Cogent Biosciences files for USD 400 million at-the-market stock offering
COGT•At-the-market equity program
Cogent Biosciences set an at-the-market equity offering of up to USD 400 million under its sales agreement with Guggenheim Securities.
Shares will be sold from time to time at market prices through or to Guggenheim Securities, acting as agent or principal.
The program is being conducted under the company’s automatic shelf registration statement on Form S-3ASR filed on Nov. 7, 2025.
Related News
MPLX LP Prices $2.25B Senior Notes Offering In Three Tranches - SEC Filing
MPLX•
Caterpillar Financial Services Corporation Prices Offering Of $300 Million Medium-Term Notes, Series L, Floating Rate Notes Due 2029
CAT•
